ABOUT SPUTNIK V
Sputnik V is the world's first registered vaccine based on a well-studied human adenovirus vector platform. It has been approved for usage in 71 countries with a total population of 4 billion people.
The vaccine name comes after the first Soviet space satellite. The launch of Sputnik-1 in 1957 reinvigorated space research around the world, creating a so called “Sputnik moment” for the global community.
The vaccine’s efficacy is 97.6%, based on the analysis of data on the incidence of coronavirus among Russians vaccinated with both vaccine components between December 5, 2020 and March 31, 2021.
Phase 1 and 2 clinical trials for the vaccine were completed on August 1, 2020. The Phase 3 clinical trial results were published in Russia in the Lancet magazine on February 2, 2021. Phase 3 clinical trials of Sputnik V have also been successful in the UAE, India, Venezuela and Belarus.
The Sputnik V vaccine is based on a proven well-studied human adenovirus vector platform; these vectors cause the common cold and have plagued humanity for millennia.
Sputnik V was the first coronavirus vaccine to use a heterogeneous boosting approach based on 2 different vectors for 2 vaccine shots. This approach generates a more sustainable immunity compared to vaccines that use the same delivery mechanism for both shots.
The safety, efficacy and lack of long-term adverse effects of adenovirus vaccines have been proven in more than 250 clinical trials over two decades.
Sputnik V does not cause severe allergies.
The Gamaleya Research Institute of Epidemiology and Microbiology announced that it had developed the vaccine without serious side effects.